TGTX250117P50000
- 32.80
- 0.000.00%
TG Therapeutics Newsroom
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy
Institutional Investors Have a Lot Riding on TG Therapeutics, Inc. (NASDAQ:TGTX) With 75% Ownership
8 Health Care Stocks Whale Activity In Today's Session
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?
Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts
TG Therapeutics Analyst Ratings
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $55
Strong Financial Outlook and Strategic Growth Opportunities Bolster Buy Rating for TG Therapeutics
TG Therapeutics Reports Strong Revenue and Future Goals
TG Therapeutics Shares Climb 7% as Sales Grow for Multiple Sclerosis Drug
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $38
B.Riley Financial Reaffirms Their Buy Rating on TG Therapeutics (TGTX)
What's Going On With TG Therapeutics Stock Tuesday?
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $10
TG Therapeutics Expects Q4 BRIUMVI US Net Product Revenue Of $103.6M, FY24 RIUMVI US Net Product Revenue Of $310M, FY25 Total Revenue Of $540M
Express News | TG Therapeutics Inc Qtrly Briumvi U.S. Net Product Rev Expected to Be $103.6 Mln
TG Therapeutics Sees 2025 Rev $540M >TGTX
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference